Combination Therapy for the Treatment of Pancreatic Cancer

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 16, 12 Issues, 2016


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Combination Therapy for the Treatment of Pancreatic Cancer



Anti-Cancer Agents in Medicinal Chemistry, 11(5): 418-426.

Author(s): William Greenhalf and Amy Thomas.

Affiliation: Department of Molecular and Clinical Cancer Medicine, the University of Liverpool, UK.

Abstract

Treatment of pancreatic cancer should be a relatively simple clinical problem, all that is needed is to find the features of pancreatic cancer cells that distinguish them from normal cells and target these differences. This is the basis of current therapies including gemcitabine and 5-FU which target DNA synthesis. Unfortunately, cancer cells become resistant to these therapies: By exclusion of drugs from cancer cells; by changes in enzymes metabolising the drugs; or by becoming more resistant to stress and apoptosis. Increasing levels of the drugs is limited by their somatic toxicity so numerous alternative therapies have been proposed. Testing these alternatives in clinical trials will be difficult unless they work with the standard treatments (e.g. gemcitabine). To date most work has concentrated on combining different S-phase targeting agents. Further incremental increase in survival benefit should be possible by targeting resistance to apoptosis, targeting stroma or even targeting multiple pathways in combination with gemcitabine.

Keywords:

Pancreatic cancer, Pancreatic ductal adenocarcinoma, chemotherapy, novel therapy, combination therapy, targets, pathways, apoptosis, tumour microenvironment, drug resistance, toxicity.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 11
Issue Number: 5
First Page: 418
Last Page: 426
Page Count: 9
DOI: 10.2174/187152011795677391
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science